The Clinical Review Committee: Impact of the Development of In Vitro Diagnostic Tests for SARS-CoV-2 Within RADx Tech.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

1. Testing Technologies as Enhancers of Disease Intervention Specialist Activities: Applying Lessons From COVID-19.Sexually transmitted diseases · 2023
   Article
2. Review of HIV Self Testing Technologies and Promising Approaches for the Next Generation.Biosensors · 2023
   Review
3. Challenges in Use of Practice-based Research Networks for a Medical Device Trial to Detect SARS-CoV-2.Journal of primary care & community health
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

16 authors at 6 institutions in 1 country.

Funding

Abstract

Indexed as